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ABSTRACT 
Proponents of the emerging field of P4 medicine (defined as personalized, 
predictive, preventive and participatory) argue that computational integration 
and analysis of patient-specific “big data” will revolutionize our health care 
systems, in particular primary care-based disease prevention. While many 
ambitions remain visionary, steps to personalize medicine are already taken via 
personalized genomics, mobile health technologies and pilot projects. An 
important aim of P4 medicine is to enable disease prevention among healthy 
persons through detection of risk factors. In this paper, we examine the current 
status of P4 medicine in light of historical and current challenges to predictive 
and preventive medicine, including overdiagnosis and overtreatment. 
Moreover, we ask whether it is likely that in silico integration of patient-specific 
data will be able to better deal such challenges and to turn risk predictions into 
disease-preventive actions in a wider social context. Given the lack of evidence 
that P4 medicine can tip the balance between benefits and harms in preventive 
medicine, we raise concerns about the current promotion of P4 medicine as a 
solution to the current challenges in public health. 
keywords: personalized medicine; systems medicine; primary care; systems biology; 
p4 medicine; medicalization; big data; disease prevention; overdiagnosis. 
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1. Introduction 
An important goal of in silico medicine is to improve biomedical research 
through computational integration of big data. This paper examines the 
challenges of implementing systems medicine (the medical application of 
systems biology) in primary health care. Specifically, we focus on the 
ramifications of strategies aiming to improve disease prediction and prevention 
through personalization of medicine, a concept promoted as P4 medicine that 
is predictive, preventive, personalized and participatory (Alyass et al., 2015; 
Benson, 2016; Duffy, 2015).  
The goal of personalized medicine is as old as the profession, and can 
broadly be defined as the aim to account for those factors that make health and 
disease specific for each individual. What is new about P4 medicine is its 
emphasis on doing so “in silico” via data-integration, and “in socio” via patient 
participation in data collection and disease prevention. P4 medicine is based 
on the expectation that “big data” technologies can account for an increasing 
number of factors that influence health and disease, and that these data can be 
used to stratify the population and health problems according to various 
characteristics. Big data here refers to patient-specific data from various 
sources such as genomics, “phenomics” technologies that enable monitoring 
and self-monitoring of phenotypic biomarkers, health records, as well as 
“exposomics” that provide inputs on environmental exposure (Flores et al., 
2013; Gjuvsland et al., 2013; Wild, 2012). The hope is that in silico 
computational integration of these data will generate a more complete 
understanding of each person´s health, better risk predicting algorithms and 
effective preventive strategies. In socio, its implementation in the context of 
each socially embedded person´s life requires a change in the current structure 
of health care towards increasing patient participation in data collection, self-
management and prevention of future diseases. Through these strategies 
proponents expect that P4 medicine will increase the quality of care and lower 
the escalating costs of health systems (Bousquet et al., 2011; Flores et al., 
2013; Kirschner et al., 2013; Diaz et al., 2013). 
So far, important discussions about personalized medicine have considered 
ethical and legal issues such as informed consent, disclosure dilemmas, 
personal identity, data security, as well as the current discrepancy between 
marketing and the utility of genomic risk profiling (Bartol, 2013; Reydon et 
al., 2012, Rehman-Sutter & Müller, ed., 2009; Forgò et al., 2010; Juengst et 
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al., 2012). Our scope is wider in examining P4 medicine in general, and in 
discussing the overall clinical utility of the new preventive strategies for 
improving public health systems.  
While P4 medicine also aims to target established disease with higher 
precision, we will focus on its primary strategy – to keep people healthy 
through individually targeted predictive and preventive medicine: 
Systems medicine aims at predicting the course of a disease in a given patient 
and how far it can be altered by available therapies. (…) The fundamental 
principle of systems medicine should thus be the prediction of benefit–risk for 
a single subject, a group, or a population” (Boissel et al., 2015, p. 138). 
While P4 medicine aims to target the course of established disease with higher 
precision, P4 medicine also involves a stronger focus on healthy people 
through a more expansive and life-long detection of early disease and risk-
factors using more data – literally “billions of data points” (Bousquet 2011, p. 
7). In other words, P4 medicine constitutes a new form of continual screening 
process, which is unprecedented in intensity and scope (Vogt et al., 2016, 
Diamandis, 2015). For the balance of benefits vs. waste and harm to turn out 
positive, this radical expansion seems to presuppose very significant gains in 
the overall utility of preventive medicine. In this paper we examine challenges 
involved in achieving such a meaningful balance. Particularly, we critically 
examine an assumption that is often taken for granted, namely that large scale 
computational integration and analysis of “big” health data will lead to a 
preventive medicine with a more adequate utility (i.e. balance of benefits vs. 
harms and costs) (Flores et al., 2013; Kirschner et al., 2013; Topol, 2012). 
The authors of this article bring together practice-oriented philosophy of 
science (SG) and philosophically oriented general practice (HV)1 in an analysis 
of the clinical utility and societal implications of P4 medicine. In the context of 
the current paper, clinical utility is related to the concept of “actionability” 
used by proponents of P4 medicine (Hood et al., 2012). Utility and 
actionability presuppose not only that the early detection of disease and risk 
assessments have a high clinical validity (accuracy), predictive and prognostic 
power, but that they can be coupled to actions that show clinical efficacy and 
 
1 General practice (or family medicine) is the medical specialty that focuses on the whole patient, as opposed 
to subsystem-focused specialties. It is part of primary care, and often the point of access and “gate-keeper” 
to care. General practice is where most medical disease prevention takes place.  
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effectiveness as well as an adequate balance of benefits and harms in a wider 
clinical and societal context (Burke, 2014).  
Thus, successful implementation of P4 medicine not only depends on its 
ability to accurately predict disease (detect very early signs of disease or risk 
factors), but also on its ability to translate these predictions into meaningful 
disease-preventive actions. The latter aspect requires that the strategies can 
work in clinical practice and people´s socially embedded lives. Historically, 
social aspects were at the center of personalized medicine as it was initially tied 
to a humanistic movement focusing not only on bodily fragments, but the 
uniqueness, experience and agency of the whole person over time (Cassell, 
2010; Tutton, 2014). But whereas personalized medicine historically 
emphasized the person´s social context and the doctor-patient relationship, 
P4 medicine rearticulates the same goal via quantitative in silico models. This 
raises important questions about whether factors concerning social and human 
biocomplexity are sufficiently accounted for in strategies laid out to reach the 
ambitious goals of P4 medicine. 
It may be objected to our analysis that these ambitious goals should not be 
taken seriously at this point. P4 medicine mostly exists as a set of promises 
about the future, and the published claims about the future of medicine may be 
seen merely as rhetorical strategies driving the competition for research 
funding. Admittedly, the above promises of P4 medicine are made with varying 
degrees of boldness, and current views on their soundness differ (Diamandis, 
2015; Joyner & Paneth, 2015). However, they are published in scientific 
contexts, and accordingly may generate expectations and actions that influence 
choices concerning prioritization, funding and implementation of medical 
research and health strategies. Accordingly, we believe that researchers have a 
scientific responsibility to calibrate their promises to what can actually be 
expected of their methods and the consequences their claims may have 
(Forssén et al., 2011). We thus find it crucial to critically examine the 
promises, and the available evidence that may justify them. In the current paper 
we combine an analysis of P4 medicine´s science visions with historical 
insights into the challenges of disease prediction and prevention. Particularly, 
we highlight lessons from personalized genomic medicine and material 
summarizing the concrete results from a dedicated P4 medicine pilot project, 
the Seattle Institute for Systems Biology´s ‘Hundred Person Wellness Project’ 
(Hood et al., 2015a).  
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We begin by relating the promises of P4 medicine to the historical and 
current challenges in preventive medicine, particularly by examining the 
problems of producing findings of unknown significance, overdiagnosis, and 
overtreatment (Section 2). By examining the current status and future plans for 
P4 medicine, we then ask whether it is likely that in silico medicine will be able 
to better deal with such challenges by computational integration of patient-
specific data. Section 3 examines the challenges faced for disease prediction, 
whereas Section 4 analyzes the challenges of turning risk predictions into 
disease-preventive actions in a wider social context. We point to the lack of 
evidence that P4 medicine can deal with the described challenges and raise 
concerns about the current promotion of P4 medicine.  
2. Challenges of Waste and Harm: P4 Medicine in Light of the History of 
Preventive Medicine 
2.1. A ‘tipping point’ in preventive medicine 
As a form of individual-centric preventive medicine, P4 medicine establishes 
itself as the latest chapter in a longer story starting with the establishment of 
hypertension as a treatable risk factor for cardiovascular disease in the 1960s 
(Welch 2011, chapter 1; Getz 2006; Hamilton et al., 1964).  
Individualized disease prevention has been associated with continued 
promises and high expectations (Yach and Calitz, 2014). It has certainly had 
its merits, but its success must be understood as relative to the problems it tries 
to solve, the expansiveness of its measures, costs and harms. Generally, 
preventive medicine has been most successful in cases where there is a 
relatively simple and strong relationship between risk factors and disease, e.g. 
patients with an established organ disease diagnosis or well people at very high 
risk (4S Study Group, 1994; Welch et al., 2011, chapter 1; Hamilton et al., 
1964). However, preventive medicine has turned to more challenging 
problems, notably prediction and prevention of complex, non-infectious 
disease in a population of predominantly asymptomatic people at lower risk of 
disease. Compared to people at high risk, this demands more of the test´s 
capacity to predict disease and raise the probability high enough for action to 
be justified. In such cases, a higher number of patients must generally be 
treated in order to change one outcome (“number needed to treat”). In this 
110  Humana.Mente – Issue 30 – June 2016 
  
endeavor, preventive medicine has met with consecutive realizations that these 
problems are harder to tackle than expected. 
Responding to these realizations preventive medicine has made its 
predictive and preventive efforts more expansive and complex, taking an 
increasing number of bodily factors and aspects of life into account. Critically, 
disease concepts have been widened by lowering diagnostic thresholds for 
what is regarded as “disease”, “early disease” or “at risk” for each of these 
factors, thereby redefining an increasing number of people as in need of 
medical attention. An expanding number of risk factors in terms of biomarkers 
have been defined (Skolbekken, 1995; Getz, 2006, Petursson et al., 2009a, 
2009b). As a corollary, clinical efforts have also expanded with more 
intervention strategies based on more measurements, including examinations 
of asymptomatic people to detect early disease or risk states (screening). As a 
result the scientific and clinical endeavor itself has been complexified, with 
more data to integrate and interpret, requiring more comprehensive and 
complex strategies. 
P4 medicine may thus be seen as the culmination of a series of increasingly 
expansive efforts to improve predictive and preventive strategies to deal with 
the complexity of human biology and clinical practice. Today, we will argue, its 
advent coincides with a historical “tipping point” in the overall balance of 
benefits vs. harms and costs in preventive medicine (Starfield et al., 2008). On 
the whole, the strategies involved, such as implementation of preventive 
clinical guidelines, general health checks, screening and lifestyle counselling, 
seem not to work as effectively as expected in practice (Fretheim, 2007; 
Hetlevik, 1999; Krogsbøll et al., 2014; Jørgensen et al., 2012, Look Ahead 
Research Group, 2013). The reasons for this may be multi-layered. As one 
element, doctors may not follow guidelines (Ashenden et al., 1997; Hetlevik et 
al., 2008; Austad et al., 2015; Boyd et al., 2005). Another key problem is 
non-compliance of patients, particularly lack of response to risk assessments 
with sustained lifestyle changes (see Section 4). More fundamental, however, 
are concerns about negative effects of preventive strategies. 
As a consequence, the last 20 years have seen an increasing concern in 
mainstream medicine about the overall utility, i.e. the balance of benefits and 
harms, of preventive medicine´s expanding efforts (Fisher & Welch, 1999; 
Sackett, 2002; Heath, 2013; BMJ; JAMA Internal Medicine). The waste and 
harm involved may be both indirect in terms of opportunity costs, where 
personnel and resources are diverted away from other issues, and direct in 
                     
                     Personalizing Medicine: Disease Prevention in silico and in socio               111 
 
terms of unnecessary side-effects and costs of diagnostics and treatments 
(Fisher & Welch, 1999; Welch et al., 2011; Heath, 2013; Moynihan et al., 
2012; Hofmann, 2014). Although negative consequences are often not 
registered in trials (Heleno et al., 2013), and results are contradictory, 
diagnostic labelling and preventive measures have been associated with harm, 
e.g. distress and reduced quality of life (see e.g. Jørgensen et al., 2015; Haynes 
et al. 1978; Brodersen & Siersma, 2013). To understand the basis for the 
discussion of waste and harm, the following section will introduce key concepts 
denoting the important challenges of preventive medicine relevant for P4 
medicine. 
2.2. Key concepts in discussions on waste and harm 
One way to conceptualize the expansion of preventive medicine described in 
Section 2.1. is as medicalization (Maturo, 2012). We will here define 
medicalization as the process by which aspects of life are defined in medical 
terms and underlain medical control (Vogt et al., 2016). Importantly, this 
definition does not imply that medicalizing an aspect of life is inherently 
negative. A main aim of medicine is beneficent control. However, any attempt 
to establish medical control comes with caveats of waste and harm (i.e. 
overmedicalization). 
Perhaps the most banal problem involved in medical testing is what we can 
call findings of unknown significance. Any clinician, having for example used a 
biomarker to screen a patient, knows the feeling of getting test results back not 
knowing what to make of them, especially in light of uncertainties about the 
test’s predictive power, the individual´s complex situation and the potential 
benefits and harms of further testing and treatment. Another, but related 
problem is false positives, i.e. tests that turn out positive when the person in 
fact does not have the disease (or risk factor). The opposite is the case for false 
negative results. 
Overdiagnosis has been claimed to be “the biggest problem posed by 
modern medicine” (Welch et al., 2011, conclusion). It is defined as situations 
where an actual disease or risk factor is diagnosed in people who are mostly 
well, and where this condition will not actually come to influence future health, 
either because it disappears spontaneously without medical attention or 
remains asymptomatic until death from other causes. Overdiagnosis is hard to 
measure; it is not possible to know at the time of diagnosis exactly who will 
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suffer, but in theory those overdiagnosed can only be harmed (Brodersen et al., 
2014, Hofmann, 2014). Overdiagnosis may also refer more generally to 
overmedicalization and processes leading to reclassification of asymptomatic 
or low risk individuals as in need of medical attention and subsequent 
overtreatment with a questionable balance of benefits and harms (Moynihan et 
al., 2012).  
Whereas the optimism for improved health benefits of population 
screening was high in the 1990s and 2000s, recent meta-analyses show that 
intensified screening is strongly associated with higher rates of overdiagnosis 
and overtreatment (Moynihan et al., 2012). The difficulties of identifying the 
cases where risk factors or early signs of disease will pose future health 
problems is particularly telling if we consider screening programs for cancer. 
Despite strong associations between genetic risk factors and breast cancer, and 
despite 30 years of experience and development of advanced methods for early 
detection (mammography), the rate of overdiagnosis of breast cancer has 
turned out to be high (Løberg et al., 2015). It is estimated that 30%, or 
approximately 1,3 million women, diagnosed with breast cancer have been 
overdiagnosed because the tumors would not have developed into health 
problems (Jørgensen & Gøtzsche 2009; Bleyer & Welch, 2012). This raises 
important questions about the utility of population screening programs (Biller-
Andorno & Diamandis 2015; Gøtzsche 2015; Biller-Andorno & Jüni, 2014; 
Gøtzsche & Jørgensen, 2013; see however Puliti et al., 2012 for a more 
positive view). Strikingly, the mortality rates not only for breast cancer but also 
for thyroid cancer, melanoma, kidney cancer, and prostate cancer have 
remained largely unchanged from 1975-2005, despite increasing rates of new 
diagnoses and treatment (Moynihan et al., 2012). 
On a more general level, one key cause of waste and harm may be 
fragmentation. An editorial in the Annals of Family Medicine states: 
Underlying the current healthcare failings is a critical underappreciated 
problem: fragmentation — focusing and acting on the parts without adequately 
appreciating their relation to the evolving whole. This unbalance, this 
brokenness, is at the root of the more obvious healthcare crises of 
unsustainable cost increases, poor quality, and inequality. Fragmentation is at 
the heart of the ineffectiveness of our increasingly frantic efforts to nurture 
improvement” (Stange 2009, p. 100). 
Human health problems have been categorized according to more minute 
bodily parts, and each factor is treated in separate “silos” of medicine (Parekh 
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& Barton, 2010). The sum of these parts, each with their diagnostics and 
treatments, adds up to “too much medicine”, which may be wasteful, harmful 
and unmanageable in practice (Getz et al., 2005; Petursson, 2009b; Hetlevik 
et al., 2008). 
One answer to the above challenges in preventive medicine is that science is 
simply not good enough in tackling the complexities and fragmentation 
involved, and that the solution lies in technoscientific breakthroughs. This is 
the position of P4 medicine (Vandamme et al., 2013). As proponents of P4 
medicine also point out, current evidence-based prevention strategies are 
based on studies of large populations and therefore fail to capture patient-
specific variation, thus potentially leading to poorer predictions and 
interventions, waste and harm (Topol, 2012).  
However, what is at the same time often named as the foremost driver of 
increased medical costs and harm – notably also when it does have beneficial 
effects – is novel technology that enables more sensitive detection of disease 
and medical risk as well as attempts to improve prognosis (Bodenheimer, 
2005; Callahan, 2008; Dybczak & Przywara, 2010; Moynihan et al., 2012; 
Hofmann, 2015). Yet, a solution based on more technology is precisely the 
promise of P4 medicine. This highlights the question whether P4 medicine can 
achieve a useful balance between benefits and harms. 
3. The Utility of P4 Medicine: Disease Prediction in Clinical Practice 
Based on the above discussion on the balance of waste and harm in screening 
and preventive medicine, we will now divide our further discussion of P4 
medicine in three: In 3.1, we will discuss P4 medicine in light of lessons from 
personalized genomics, its immediate predecessor in preventive medicine. In 
Section 3.2, we will discuss early results from the first project that aims to 
pioneer in silico systems medicine. In 3.3, we look to the future and ask if we 
can expect more data and systems medicine to overcome tip the balance of 
utility in preventive medicine favorably. Our focus will mainly be on the 
diagnostic side and challenges of disease prediction, and less on the 
development of treatments for complex disease. However, we must underscore 
that this is an equally crucial step worthy of a publication of its own. If the 
prediction has no associated effective treatment, it is not actionable. 
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3.1. Genomic strategies and personalized genomics 
The completion of the Human Genome Project was an important step in the 
development of  biomedical, personalized medicine. Since the completion of 
the first human genome in 2003, the time and costs of sequencing of a human 
genome has decreased exponentially, enabling personalized genomics for large 
population groups. At the moment of writing, initial steps towards the 
development of personalized medicine are taken through the investment in 
large-scale projects such as the “Precision medicine initiative” (US) and the 
“100,000 genomes” (UK) project (Collins & Varmus, 2015; Marx, 2015). In 
addition to detailed whole genome sequencing, a prominent form of research 
underlying efforts in personalized genomics is genome-wide association 
studies (GWAS). The basic procedure of GWAS is to scan for genetic variants 
that are statistically significant when comparing two groups, typically a group 
with and without a specific disease. Risk alleles, or single nucleotide 
polymorphisms (SNPs), are said to be associated with a specific disease if its 
appearance among a group with a given disease is statistically significant 
compared to a group without the disease. GWAS have the dual aim of 
identifying new disease-related genetic variants for research purposes and to 
use the statistical estimates of disease risk for individualized disease 
prevention.  
However, such GWAS-based efforts have already run into challenges of 
biocomplexity and prediction. To understand this we need a small historical 
detour. GWAS studies were originally designed to test the “common disease–
common variant hypothesis”, i.e., that common genetic variants could explain 
a large proportion of the variation in common diseases (McPherson & 
Tybjaerg-Hansen, 2016). Significantly, biologists warned from the beginning 
that:  
The common disease/common variant model is elegant, appealing and 
politically correct, but there are objections. The essential one is that it 
fundamentally misrepresents the nature of common disease. By definition, 
complex traits have (…) a low probability of carrying any particular 
susceptibility genotype given that the individual has a particular disease or trait 
phenotype. This is because, unlike Mendelian disorders, common diseases 
clearly result from the interaction of many genetic and environmental 
influences, so that the correlation with any one factor is weak” (Wright and 
Hastie 2001, p. 2). 
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The problem is here that each genetic biomarker has only a weak or modest 
association with a complex disease or incomplete penetrance.2 In other words, 
a very large number of genes, each with small and context-dependent effects, 
are involved in determining disease and the exact causal relationship is 
complex and unknown (McPherson & Tybjaerg-Hansen, 2016). Researchers 
have major difficulties accounting for the heritability in terms of specific 
genetic variants even in cases where the heritability of a disease is high (Maher, 
2008). This has created discussions about explanations for the “missing 
heritability”. Some have suggested that the total heritability may be 
significantly inflated by gene-gene and gene-environment interactions, 
creating “phantom heritability” (Zuk et al., 2012). The importance of dynamic 
interactions means that the causal influence of any particular genetic risk factor 
is not stable and additive, but dependent on the biological and environmental 
context. This has discouraging implications of the predictive potential of gene 
tests (Wallace, 2012). While it was previously hoped that one could find 
variants that multiplied the risk 600%, the detection of variants rarely increase 
the probability of disease by more than 50% (Joyner &Paneth 2015; Kaiser 
2012). This decreases the utility of such findings. While 50% may sound 
substantial, remember that when the probability of any given disease is initially 
low, which is often the case in well individuals, the test needs to raise the 
probability of disease substantially to add something useful to clinical 
judgement. 
The aforementioned issues do not reject the potential for genomic 
strategies to play important roles as correlation-based research heuristics to 
identify candidate gene variants for further causal analysis. However, important 
concerns are raised in cases where SNP analyses are used as what Austin and 
colleagues (2013) call “shot-gun testing”, i.e., simultaneous screening for 
multiple risk factors (e.g. in consumer genomics today). The (often unknown) 
causal complexity and incomplete penetrance between genetic variants and 
disease increases the challenges outlined in section Section 2, as we clarify 
below. 
 
2 Penetrance of a mutation is a statistical measure for the phenotypic impact of a genetic variant.  
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3.1.1. Personalized genomics: Variants of unknown significance 
With new genomic strategies, the problem of findings of unknown significance 
has greatly increased in terms of so-called variants of unknown significance 
(VUS). As one commentator working within genetics puts it, genome data 
today are ”routinely failing to reveal useful insights about disease in general or 
a person’s health in particular” (Cooper, 2015, p. 1423). In many cases, 
information about genetic associations is no more predictive of disease risk 
than factors such as family history, environmental risk, age, blood pressure etc. 
(Hall et al., 2010; Joyner &Paneth 2015). According to Cooper, “Such 
variants are trapped in the interpretive void between “benign” (i.e., definitively 
not relevant to disease) and “pathogenic” (i.e., definitively relevant to 
disease)” (Cooper 2015, p. 1423). What is deemed significant is also not only 
objective, but a culturally situated and value-laden act of interpretation: “Your 
VUS may be my diagnosis, depending on the manner in which we use the 
information and the weights that we place on the consequences of false positive 
and false negative conclusions” (Ibid., p. 1424). 
3.1.2. Personalized genomics: False positives and false negatives 
Uncertainties associated with genetic markers, the cumulative effects of these, 
and sampling procedures for GWA approaches also increase the problem of 
false positives and negatives (Ng et al., 2009; Tutton, 2014). On the basis of 
the expected high numbers of such results, critics of consumer genomics have 
stressed concerns about increased and unnecessary anxiety about future 
diseases and risk information, or a false sense of “genetic immunity” from 
these (e.g., Ransohoff & Khoury, 2010). Such concerns have not been 
sufficiently supported by empirical studies of self-reported reactions from early 
users of consumer genomics (Nordgren, 2014; O’Daniel et al., 2010). 
However, it can be questioned whether early users are representative of the 
general public, as admitted by the authors of one of these studies (MacGowan 
et al., 2010). This point is particularly important at the background of other 
studies documenting psychological distress associated with false positive 
results in the context of risk profiling for breast cancer (Brodersen & Siersma, 
2013). 
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3.1.3. Personalized genomics: Overdiagnosis 
The cancer researcher Gilbert Welch has stated that genetic testing should be 
considered the ultimate form of overdiagnosis, as virtually everyone will be 
diagnosed with risk factors (Welch et al., 2011). Many genotypes are weak 
predictors and, “Overdiagnosis and penetrance are inversely related. The less 
penetrant a gene is, the more overdiagnosis will occur, because most people 
with low-penetrance genes will not in fact go on to develop the disease” 
(Welch et al., 2011, chapter 9). 
Generally, the benefits and harms of predictive and preventive 
interventions are not only influenced by the sensitivity of the testing 
procedures, i.e. their ability to detect disease, but also by factors associated 
with the absolute risk of a certain group. For instance, screening for different 
types of cancer is typically recommended only for particular age groups or for 
people with a higher expected risk due to their family history. Of particular 
relevance for further investigation is therefore whether personalized genomics 
can help identify the individuals for which further screening and monitoring is 
advisable. If so, personalized genomics could help health care providers tailor 
screening programs only to individuals that are most likely to benefit from 
these. Yet, we must in this context keep in mind the levels of uncertainty for 
shotgun tests for risk factors with low penetrance, compared to more 
traditional genetic tests for BRCA mutations and the concerns mentioned in 
Section 2 about overdiagnosis in screening programs. 
3.2. Early evidence of P4 systems medicine in practice 
With GWAS and personalized genomics, P4 medicine started out as a gene-
centric project, focusing mostly on DNA. However, P4 medicine has 
increasingly seen the need to account for biological systems as wholes, whether 
in terms of whole pathways, whole cells, whole organs or even the whole human 
organism as a system of systems (Bjørnson et al., 2016; Flores et al.; 2013; 
Diaz et al., 2013). It is this development that is called systems medicine. So 
far, attempts to increase the predictive power of testing by using algorithms 
that combine several variables (e.g. smoking, cholesterol, blood pressure) have 
lead to misclassification and overclassification of risk status (Getz et al., 2005; 
Petursson et al., 2009b, 2012; Kolata 2010; van Staa et al., 2013). Although 
some significant progress has been made (Mega et al., 2015), the addition of 
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genetic information to such algorithms has generally also had limited success 
(McPherson & Tybjaerg-Hansen, 2016; Smith et al., 2015). This has strong 
relevance for P4 medicine, which acknowledges the weaknesses of previous 
tests, but promises to overcome the complexity involved by increasing the 
number of variables dramatically. As a tell-tale development, cardiovascular 
disease prevention, which started out 50 years ago with hypertension as a 
single biomarker, is now moving towards the use of high-throughput 
methodology and systems biology to improve prediction and prevention 
(McPherson & Tybjaerg-Hansen, 2016; Bjørnson et al., 2016). Thus, both 
the data and proposed algorithms involved in systems medicine are becoming 
even more complex. As preventive medicine stands at the tipping point 
described in Section 2, and the journal JAMA Internal Medicine (see reference 
list) as one example highlights “less is more”, P4 medicine proposes to tip the 
balance of benefits and harm through even more medicine. 
A project that may be seen as defining for the current status of P4 medicine 
is the Hundred Person Wellness Project (HPWP), performed in 2014 by the 
Institute for Systems Biology (ISB) in Seattle and prominently featured in 
Nature (Gibbs, 2014). This pilot study is important for our purposes, as it is 
the first real-world test of P4 medicine as conceptualized by the key visionary, 
biologist Leroy Hood.  
The HPWP pioneers the most radical medicalization of human life in 
history. In total, 107 participants, mostly Caucasian, middle class and 
predominantly asymptomatic persons were included, each constituting a form 
of n-of-1 research project over 10 months. They were underlain a regime of 
fine-grained, multi-level and longitudinal monitoring aimed at the earliest 
possible detection of disease and risk factors, that is, a continual screening 
process of unprecedented scope. According to Hood et al. (2015a), patient-
specific data were collected in “four main areas: 1) whole genome sequencing; 
2) clinical and functional laboratory testing (every three months); 3) gut 
microbiome (every three months); and 4) quantified self and traits (physical 
activity, sleep, weight, blood pressure, personality and lifestyle factors, and so 
on)”. These data were used as a basis for advice from health coaches (a novel 
primary care professional). In addition, a variety of proteomic and metabolomic 
markers were measured, creating individualized clouds of billions of data 
points for each individual to be computationally integrated and mined. The 
researchers aim to expand the HPWP to 100,000 participants in a “100 K 
Wellness project”.  
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Little empirical evidence has been published about the clinical utility of P4 
medicine or the HPWP. Recently, however, some early results from the HPWP 
and cases that are used as “proof of principle” narratives have been described. 
In our below discussion of these reports, the concept of actionability and “an 
actionable”, which is frequently used by Hood and coworkers will be central. 
Hood & Price (2014, p. 22) have vaguely defined “an actionable possibility” 
as “a feature for an individual that, if corrected, could improve wellness or 
avoid disease”. 
3.2.1. Actionable gene variants: The case of vitamin D 
Personalized genomics forms an integral basis of the HPWP and P4 medicine, 
and we will first examine this element in light of Sections 2 and 3.1. In their 
promotion, Hood and colleagues refer specifically to the concept of an 
“actionable gene variant”, defined as a defective gene “that allows a physician 
to specify how a patient may improve his or her health” (Hood et al., 2012, p. 
5). Furthermore, they claim that, “It is the continually increasing number of 
actionable gene variants that will be the major driver in having society accept 
whole genome sequences as an important part of each person’s medical 
record” (Ibid, p. 5). Hood (2013, p. 9) claims that, “All individuals will benefit 
from sequencing their genome” due to the identification of such variants, and 
furthermore that “We have identified almost 300 highly penetrant variants that 
fall into the actionable gene variants category”. Many of these “actionables” 
are supposedly linked to nutritional deficiencies (Hood & Price, 2014). In 
light of sections 2 and 3.1, this seems a high number, and we may ask: Why 
should these variants be regarded as “actionable”? 
Hood and colleagues have in various publications exemplified what they 
mean by an “actionable gene variant” by describing the case of a man that is 
diagnosed with a gene that codes for a malfunctioning vitamin D transporter 
protein (Hood et al., 2012; Hood, 2013; Hood & Price, 2014). This variant is 
described as potentially leading to osteoporosis with early onset. The man is 
then described as being able to reverse this condition and prevent it from 
reoccurring by taking over time x20 the normal dose of vitamin D (or calcium 
according to Hood & Price, 2014).  
Should this genetic variant actually be considered “actionable” in the sense 
Hood and colleagues define it above, and what does this mean for the status of 
the other 300 variants referred to? As Hood and colleagues do not refer to 
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clinical or other research on the 300 variants or the vitamin D case, which (as 
far as we can see) has not been described in a separate publication, this is 
unclear. However, from what is recounted the treatment in the case seems to 
be based solely on physiological reasoning about disease mechanisms. In 
general, this kind of reasoning has a problematic track record in medical 
decision-making (e.g., Echt et al., 1991). Additionally, Hood and colleagues 
do not mention eventual side effects of the x20 dose of calcium/vitamin-D. 
Taking vitamins (or calcium) may sound innocent, but side effects should 
always be taken into account. However, our main point here is that as an 
example of how “actionability” or “clinical utility” should be understood in P4 
medicine, this case fails to give a clear and persuasive account. 
3.2.2. Results and utility of the HPWP 
Three publications and one plenary speech provide some preliminary results 
from the HPWP (Hood et al., 2015a; 2015b; Schmidt, 2014; Hood 2014): 
 The project diagnosed “multiple ‘actionable possibilities’ for each 
participant” (Hood et al., 2015b). 
 57% were diagnosed with an actionable “cardiovascular pattern” 
(abnormal lipids, particle size or density), 53% with an “inflammation 
pattern” (elevated inflammatory markers) and 63% were diagnosed 
with an actionable “nutrient insufficient pattern” (defined as 
“decreased levels of key nutrients”) (Hood, 2014). Regarding 
nutrition, the measurements had especially revealed vitamin D 
deficiency (Schmidt, 2014). Recommended actions against these 
“actionables” ranged from medication and supplements to dietary 
change, exercise, weight loss and stress management (Hood, 2014). 
 43 participants were diagnosed with prediabetes. 7 individuals were 
reported to have normalized and “many others had favorable 
improvements” in their prediabetes markers by the end of the study 
(Hood et al., 2015b). 
Previous studies in Norway have shown that if one follows authoritative 
guidelines for disease prevention in a normal population, one would define a 
high proportion as “at risk” (Getz et al., 2005; Peturson, 2009). What is most 
striking about the above described results is that – at least as pioneered in the 
HPWP – the P4 medicine preventive strategy seems to define 100% of a 
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population of previously well as in need of medical attention. It is also striking 
that over half the population is diagnosed with a risk factor both with regard to 
CVD, nutritional status and inflammation. Of relevance, vitamin D deficiency 
and supplementation in asymptomatic people is a highly controversial issue in 
current debates on waste and harm, which is linked to poor clinical evidence as 
well as alternative medical practice (Welsh & Sattar, 2014). Also of relevance, 
prediabetes, an extension of the diabetes category with a lower diagnostic 
threshold, is a controversial case in ongoing debates on overdiagnosis as it may 
entail the downsides of being diagnosed with diabetes (costs and risk of 
treatment, challenges with insurance and employment, self-image) alongside 
questionable long-term benefit (Yudkin & Montori, 2012). 
The above firstly raises important conceptual questions. Critically, it raises 
questions as to how the diagnostic thresholds have been defined. An 
“actionable” seems to be a rebranding of a finding that predicts disease, risk or 
at least something suboptimal. However, from the P4 medicine literature, 
there is conceptual unclarity as to what an “actionable gene variant” or “an 
actionable possibility” actually should correspond to in terms of utility and 
balance of benefits and harms. One may for example ask if detection of 
“actionables” points towards something more or different from what can be 
gathered from general, traditional health advice. Therefore, more conceptual 
work on what constitutes actionability and clinical utility in P4 medicine is 
needed. 
Secondly, and most importantly, it raises questions about clinical utility. 
According to its lead scientists, many participants of the HPWP realized that 
with the information they could make decisions to improve their health and that 
“this can have enormous effects on reducing risk for downstream debilitating 
and expensive chronic and other diseases. This is central to reducing the cost 
of healthcare” (Hood et al., 2015b, p. 12). Without further documentation, 
Hood and colleagues insist that the benefits of their approach will “far 
outweigh any possible harms” (Hood et al., 2015a, p. 3). However, in light of 
our previous discussion on the history of preventive medicine, preventive 
genomics included and the enormous amounts of measurements and intensive 
management in previously well people in the HPWP, this is far from clear. The 
burden of proof should be regarded as heavy and entirely on the side of P4 
medicine researchers. 
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Consider also the law of diminishing returns, which has been referred to 
since the beginning of discussions of waste and harm in mainstream medicine 
(Fisher & Welch, 1999). First described by economists this refers to the 
general trend that the first unit of input into a system (e.g. a unit of health care) 
will provide substantial benefit. However, for additional units (e.g. tests and 
treatments) the benefit decreases, and eventually, as each additional unit can 
offer comparatively little to previous units, the benefits of “more medicine” are 
eventually outweighed by the harms and costs.  
At the time of writing, it is uncertain how much “actionable findings” add 
to current estimates of disease risk (or suboptimal health) in the individual. It is 
also unclear to what extent they can be coupled to interventions that have 
documented efficacy and effectiveness and can be predicted to change the 
prognosis in a real-life setting. The extent to which the massive number of 
“actionables” actually should be regarded as findings of unknown significance 
or overdiagnosis is thus unclear, but both must be regarded as potentially 
substantial. Screening for risk factors and an extreme focus on early detection 
of and intervention towards disease in asymptomatic people, as well as 
widening definitions of what is “actionable”, increases the probability of 
overdiagnosis (Diamandis, 2015; Moynihan et al., 2012). The researchers 
themselves do acknowledge that, “It is inevitable that screening thousands of 
data points will generate false positives, as well as false negatives” (Hood et al., 
2015a, p. 2). 
More empirical evidence is thus needed to make a qualified evaluation of 
the HPWP. However, despite available guidelines for the assessment of 
evidence for and against the public health impact of personalized genomics, 
pilot studies such as the HPWP do not follow such guidelines, nor do they 
involve controls in order to evaluate interventions (cf., Diamandis, 2015; 
Hood et al., 2015a; Khoury et al., 2012).3 Instead, the HPWP has a form of 
“n-of-1” research strategy of each individual that aims “to develop a series of 
stories about how actionable opportunities have changed the wellness of the 
participants – or made them aware of how they can avoid disease in the future” 
(Hood et al., 2015b). Although we will not dismiss such data-rich “bio-
narratives” as informative, this makes it difficult to critically evaluate the 
results, and P4 medicine risks justifying the massive medicalization with 
 
3For a reexamination of the Wilson-Jungner criteria for screening in the context of genomics and 
personalized medicine, see (Andermann et al., 2008; Diamandis, 2015). 
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anecdotal evidence. Additionally, the endpoints used in the HPWP seem 
mostly to be surrogate markers (e.g. blood sugar). However, continual 
correction of such markers is no guarantee that one can change the hard 
endpoints that actually matter (morbidity and mortality). Unless 
documentation is provided of what was actually done and achieved in the 
HPWP, the high profile project cannot be regarded as a credible scientific 
endeavor. Given its high profile in the promotion and promises of P4 medicine 
this is disconcerting. 
3.3. Is more “big data” the solution for predictive 
 and preventive medicine? 
Having recounted the story of predictive and preventive medicine so far, 
including the HPWP, we now turn to its envisioned future. As mentioned in 
Section 2, what is exciting about P4 systems medicine is its promise to 
overcome fragmentation and “to provide the tools to take into account the 
complexity of the human body and disease in the everyday medical practice” 
(Vandamme, 2013, p.1-2; see also Mayer-Schönberger & Cukier, 2013). 
Ironically, however, what initially happens in P4 medicine is the most massive 
fragmentation in medical history through the gathering of fragmented big data.  
The hope is that one can deal with multi-causality and overcome low 
predictability of complex diseases by accounting for an increasing number of 
risk factors. At least when considering the early results of the HPWP, each 
fragmented abnormal measurement seems to be taken as “an actionable”, and 
when interactions between elements are taken into account, this is promised 
only to yield even more actionables (Hood et al. 2015b, p. 13). Risk profiling 
based on self-monitoring or gene testing results in an explosion of data points 
and factors of uncertainty – a challenge that physicians are not prepared for 
(Haga et al., 2012; Stanek et al., 2012). As Jameson and Longo (2015, p. 4) 
ask, “How can physicians adapt to this daunting explosion of information and 
the associated clinical guidelines?” The concern is that the sum of the 
fragmented measurements in P4 medicine adds up to an unmanageable amount 
of isolated diagnoses, treatments and considerations, each with a risk of waste 
and harm. A central premise for P4 medicine to work in practice thus seems to 
be that the vast amount of fragmented measurements can be integrated into 
models and algorithms so that more measurements can be translated into less 
waste and harm by registering only what is actually significant.  
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Proponents of P4 medicine expect that complex models can not only 
overcome many of the problems with traditional models, resulting from 
priorities on what to measure (cf., Kolodkin & Westerhoff, 2011), but also 
help identify the relevant variables as measures of health states and stratify the 
patient groups in need of particular treatments or health-optimizing actions 
(Hood and Flores, 2013). However, it should be noted that it is not always the 
case that more data will lead to better predictive models, while it is always the 
case that it comes with the caveats described in Section 2. Whereas the initial 
expectation that access to omics data would uncover underlying disease 
mechanisms via more complex models were high, it is becoming increasingly 
clear that there are serious practical and principal limitations to the idea of 
bridging the gap between genotypes and phenotypes via more datapoints 
(Noble, 2012; Wolkenhauer & Green, 2013). As proponents of systems 
medicine themselves admit: "There is an urgent need to bridge the gap 
between advances in high-throughput technologies and our ability to manage, 
integrate, analyze, and interpret omics data" (Alyass et al., 2015). One 
challenge is that the amount of noise inherent in the data increases as big data 
are collected, and handling and integrating large amounts of data pose a 
number of substantial challenges (Benson, 2016). These challenges include 
uncertainties about and differences among experimental methods and 
sampling procedures for statistical correlation studies, making data curation a 
much more complex matter than often assumed (cf. Mayer-Schönberger & 
Cukier, 2013; Leonelli, 2014).  
Moreover, the hope of predicting and preemptively controlling disease 
raises fundamental questions about the general predictability and 
controllability of extremely complex systems (Cilliers, 2013). Such 
discussions are beyond the scope of this paper, but we wish to point to some 
lessons of systems thinking, and in particular challenges posed by the 
complexity of human biology and health, which is adapted to a complex social 
environment.  
George Engel, founder of the widely recognized biopsychosocial medical 
model, formulated the challenge facing “personalized medicine” as the 
challenge of being scientific in the human domain (Engel, 1997). “The human 
domain” is here to be understood as human biology in the widest sense, as a 
complex, dynamic system. Health and disease emerges from an interaction 
between the biological, psychological and the social levels. As a modern 
recognition of these insights, scientists are now pointing out that a gene-
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centric focus “will stymie progress” (Wild 2010, p. 1). For this reason, 
proponents of P4 medicine want to extend measurements to include 
“phenomics” (Gjuvsland, 2013) and “exposomics”, the latter of which seeks 
to represent “every exposure to which an individual is subjected from 
conception to death” including the socioeconomic and “psychosocial” (Wild, 
2010). But what are the reasons to believe that this will solve the problems 
involved in disease prediction and prevention? 
Serious challenges are met in cases where there are complex feedback 
relations between molecular and social factors and adaptation to extremely 
complex social interactions. An increasingly rich biological literature from 
fields such as psychoneuroimmunology, epigenetics, psychosocial genomics 
and epidemiology documents how social and personal (psychological) 
experience of each individual affects the cellular and molecular levels (Marmot, 
2005; Shonkoff et al., 2009; Holt-Lunstad et al., 2010; Danese & McEwen 
2010; Eisenberger & Cole, 2012). Consider, as a striking example, how it is 
documented how neural circuits – notably the vagal nerve – relay signals from 
the socially situated brain to modulate the function of immune cells (Pavlov & 
Tracey, 2015). Such results empirically substantiate how the conceptual 
divides between nature and nurture, and mind and body, are untenable 
(Kendler 2005; Beauregard, 2007; Novack et al., 2007; Noble, 2012). 
Our aim is not to reject that progress can be made, but to point out that the 
promises of P4 modeling strategies depends on the extent to which human 
biology, including the aspects we call “mental” or “psychosocial”, are 
predictable and controllable at all (Strand et al., 2004; Vogt et a. 2014). 
Already in his book, The Mirage of Health from 1959, biologist René Dubos 
forcefully argued that, “exact science cannot encompass all the human factors 
involved in health and in disease” (p. 219). P4 medicine (still) cannot 
parameterize and measure this totality. Mapping the human genome has not 
changed the view that: “The complexity of control, overlaid by the unique 
experience of each individual, means that we must continue to treat every 
human as unique and special, and not imagine that we can predict the course of 
a human life other than in broad terms’ (Sulston & Ferry, 2002, quoted in 
Noble, 2010). So far at least, we have no reason to assume that one can 
“measure everything” to faithfully or meaningfully capture the factors that 
influence human health and disease, with unknown, but potentially very 
significant consequences for disease prediction and prevention. 
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We do not deny that some or perhaps many significant predictions with 
time can be made via the P4 approach. Particularly, the clinical utility of 
genome sequencing is a moving target that may greatly increase with the 
development of reference-genomes made from deep sequencing of large 
populations. Our main issue is again with the discrepancy between the 
promises made on the hand, and the lack of evidence and theoretical 
justification that P4 strategies can deal with the complexity on the other. This 
has profound implications for the prospects of P4 medicine to improve public 
health practices. 
4. ”Participatory”: Challenges and Implications of P4 Medicine in socio 
In Sections 2 and 3 we have outlined some scientific challenges to predicting 
and preventing disease in complex human organisms through “personalized” 
in silico strategies. In this section, we widen our critique and the meaning of 
“human biocomplexity” by examining challenges and implications related to its 
implementation in a social context. Advocates of P4 medicine acknowledge 
that, “This societal challenge of deploying P4 healthcare is more daunting than 
the scientific and technological challenges facing P4 medicine” (Flores et al., 
2013, p. 5). However, they mainly point to conservative viewpoints and 
methodologies of the medical establishment, regulation issues and 
reimbursement policies favoring “disease care” over prevention (Topol, 2012, 
Flores et al., 2013). Our focus will be on a different, and arguably more 
fundamental, challenge associated with the presupposed reactions to risk 
information. The issue concerns the extent to which the norms and goals of P4 
medicine and the reality of patients are aligned. 
4.1. Will P4 risk information be “actionable” for the general public? 
Would P4 medicine be effective and useful, even if it had valid predictions and 
efficient treatments? An affirmative answer presupposes that individuals react 
to risk information by taking action to improve health outcomes via lifestyle 
changes or preventive treatments. Proponents of P4 medicine seem to assume 
that risk information consists of value-free facts that are directly translatable 
into risk-reducing actions. Moreover, they assume that the goals inherent in P4 
medicine are perfectly aligned with other goals in personal life and society (e.g. 
Hood et al., 2012; Hood and Price, 2014).  
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A view from social science reveals that response to risk information is a 
much more complex issue (Lupton, 2012; Prainsack, 2014). As noted in 
Section 2, evidence from the history of preventive medicine suggests that so-
called “compliance” issues are still immense hurdles for preventive strategies. 
Proponents of P4 medicine respond to such concerns by arguing that P4 
medicine will provide a whole new level of motivation compared to previous 
population-based healthcare. It is argued that individualized risk information 
will be perceived as more relevant, and that the immediate feedback provided 
by continual testing, primary care-based health coaching and social networking 
between participants will create “relationship-based accountability” (Hood et 
al., 2015a, p. 4; Hood et al., 2015a, p. 11). Yet, empirical studies show little 
or no effect of risk information from personal genetic risk profiling, in 
particular on health-related actions (Hall et al., 2010; Heshka et al., 2008; 
Marteau et al., 2010; Nordgreen, 2012; Roberts & Ostergren, 2013, Grant, 
2013). Moreover, a recent randomized controlled trial, which provided 
participants with common, chronic health conditions with an extensive self-
monitoring system and follow-up over 6 months, showed no short-term effects 
on health care utilization or costs (Bloss et al., 2016). 
In some cases, concerning serious hereditary diseases, attempted risk-
reducing behavior is documented in response to individual genetic risk 
profiling and thereby taken as a “proof of principle” of the benefits of P4 
medicine. For instance, a study of responses among women with a high risk of 
breast cancer considers prophylactic surgeries, screening, and encouragement 
to further testing of close relatives "a model for high-risk actionable genetic 
tests of proven clinical utility” that provide “clear benefits to participants" 
(Francke et al., 2013, p. 1; see also O’Daniel et al., 2010). However, as we 
emphasized in Sections 2 and 3, it cannot be assumed without further evidence 
that the genetic tests identify the persons for which further screening is 
advisable, or that more screening of asymptomatic individuals will result in 
health benefits and reduced medical costs (Hall et al., 2010; Biller-Andorno & 
Diamandis 2015; Gøtzsche 2015; Biller-Andorno & Jüni, 2014; Gøtzsche & 
Jørgensen, 2013). Furthermore, an important driver of cost escalation in 
health care is the introduction of medical technology itself, previously 
estimated by health care economists to be as high as 40-50% of the annual cost 
increases (Callahan, 2008).  
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These points are particularly relevant for the evaluation of the HPWP 
project. Its leading scientists recently claimed that their early results are proof 
of principle that actions of their participants are changing this picture since 
“most of them established a new and very personalized baseline for their own 
health and 70% of them acted on the coaching recommendations provided” 
(Hood et al.,  2015b). However, as it is also the case for early users of 
consumer genomics, it seems highly unlikely that the selection of a population 
of largely middle class “health enthusiasts”, a number of whom reportedly felt 
that pioneering the P4 project was “ the experience of a lifetime” (Hood et al.., 
2015b), is representative of the general population or those at highest risk. 
From a public health perspective, Burke and Trinidad (2011, p. 1) stress that 
“P4 medicine cannot solve the root problem: the need for political and public 
health action to improve the life chances of disadvantaged people. In this 
context, a realistic assessment of the prospects for systems biology is sorely 
needed”. A related concern is the potential harmful effects of risk information 
(e.g. stress and anxiety), particularly when the information most likely involves 
high rates of false positives and overdiagnoses (e.g. Diamandis, 2015). P4 
proponents have dismissed such concerns as a myth with reference to studies 
of early users of consumer genomics and highlight that health coaching is 
accompanied by information of uncertainties about test results (Hood et al., 
2015a). But, again, evidence of negative psychological effects of false positives 
in population screening programs (e.g., Brodersen & Siersma, 2013) cannot 
be dismissed with reference to studies of health or technology enthusiasts that 
are not representative of the general public. Moreover, the implementation of 
testing programs with a doubtful or unknown balance between benefits and 
harms cannot be justified with reference to informed choice (Johansson & 
Brodersen, 2015). That is, information about uncertainties does not remove 
the burden of evidence for the benefits of the tests from companies, scientists 
or health authorities.   
The idea that choices about testing can be left to individual patients is 
particularly concerning given that the majority of the general public seems to 
overestimate the benefits of screening (Gigerenzer, 2009). The cultural 
perception of screening is difficult to change, even if patients are given concise 
information about the risk of overdiagnosis (Henriksen et al., 2015). The 
cultural belief that more medicine is better, and the widespread faith in early 
detection and screening is currently considered some of the main drivers of 
overdiagnosis (Moynihan et al., 2012, Heath 2013, Hofmann 2014). 
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Moreover, a key driver of overdiagnosis is technology itself. The technologies 
of P4 medicine aim to detect ever smaller “abnormalities”, thereby widening 
the scope of medicine through a re-articulation of healthy people into “risk 
individuals”. The researchers involved in the HPWP reported that “Many 
individuals who report that they feel reasonable ‘well’, may, in fact, have 
multiple abnormalities in biochemical markers reflecting organ and system 
dysfunction, nutritional status or other health risk” (Hood et al, 2015a, p. 2, 
see also Hood et al., 2015b).  
Labelling everyone as not well enough raises the possibility that it will be 
hard to feel completely healthy for people who enter such management (Vogt 
et al., 2016). In the HPWP, all healthy individuals are at the same time 
reclassified as in need of medical attention and as actors with the possibility 
(and responsibility!) to “take action” to optimize their health. Thus, the degree 
of medicalization amounts to what can rightfully be called a social 
transformation (Flores et al., 2013). As envisioned, P4 medicine is a system 
that expects the active participation of the whole of society far beyond the 
current health system, a health society with social ties based on the common 
quest for health in networks of wellness-seeking individuals.  
4.2. P4 values vs. people values  
As we have argued throughout the paper, and as the HPWP illustrates, P4 
medicine entails a number of factors that have been associated with an 
increasingly precarious balance of waste and harm in medicine. Among these 
are the use of new technology that allows more and more sensitive 
measurements of bodily factors, and the widened scope of medicine through an 
increasing focus in healthy people and health consumerism (Moynihan et al., 
2012; Heath 2013, Hofmann 2014; Fisher & Welch, 1999; Callahan, 
2008;Welch et al., 2011; Brodersen, 2014). Moreover, the aforementioned 
assumption that more screening is safer is currently encouraged through the 
promotion of P4 medicine that is also intertwined with commercial and 
academic interests (see below).  
We have argued that P4 medicine is the, to date, most radical attempt to 
medicalize all aspects of human life (see also Vogt et al., 2016). P4 medicine is 
promoted as “holistic” in the sense that it goes beyond gene centrism and 
focuses on individual biomarkers at all levels, from molecules to personal 
characteristics, to social networks over time. Yet, to extent that it is holistic, it 
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represents a techno-scientific holism that widens and redefines health and 
wellness in quantitative terms in order to reimagine human bodies as control 
systems “which comply with medicine’s fantasies of perfect management” 
(Tutton, 2014 p. 10, quoting Waldby 2000). Thus, the intensified focus on 
disease prevention through genetic testing, extensive (self-)monitoring and 
self-regulation promotes a certain view of health as largely knowable through 
and determined by biomarkers, but controllable through informed actions of 
the individual patient and precise treatments. It is in this context that 
proponents of P4 medicine want to extend the scope of measurements to also 
include the total “exposome” (Benson, 2016), “sociometrics” (Flores, 2013) 
and social biomarkers like social networks, religious commitmens, and general 
social behavior in the algorithms (Prainsack, 2014).4 Whereas the inclusion of 
social aspects on one hand may be seen as an improvement in embracing 
human biocomplexity, and to humanize medicine, it raises concerns about the 
totality of ”surveillance medicine” (Armstrong, 1995) and its capacity to turn 
the acknowledgement of ”the human domain” into even more technoscientific 
control (Tutton, 2014;Vogt, 2016).  
These aspects should be seen in connection to commercial and professional 
vested interests in P4 medicine. P4 research and funding opportunities are 
crucially dependent on patient participation to deliver the raw material for 
analysis, namely patient-specific data. Although the new preventive strategies 
are marketed as an open choice, emphasizing the ideals of patient autonomy 
and empowerment (Topol, 2012; Hood et al., 2015a), the intensified focus on 
disease risk in P4 medicine comes with encouragements that imply particular 
social norms about responsible citizenship. In this context it is pertinent to 
note how a large group of P4 medicine advocates find it necessary to stray very 
near coercion and placing imperatives on people’s lives in order to reach their 
own goals: “patients must understand that it is their societal responsibility to 
make their anonymized data available to appropriate scientists and physicians 
so that the latter can create the predictive medicine of the future that will 
transform the health of their children and grandchildren” (Bousquet et al., 
2011, p. 3). Similarly, it is equally pertinent to ask whether patients would be 
held responsible if they refuse to react to information on risk factors 
(MacArthur et al., 2013 p. 918). In the context of preventive medicine, risk 
 
4 One example of the use of social biomarkers is a pilot study where patients with bipolar disorder were 
monitored via their cell phones (Doryab et al., 2015). 
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becomes a central organizing principle for responsible personhood and 
citizenship (see also Schwennesen et al., 2008). Yet, whether the right 
decision for the individual is to make life style changes, undergo preventive 
treatments etc. is also a matter of complex issues relating to personal and social 
values. Thus, whether risk information is “actionable”, but also whether it 
should be, are important questions to address from the outset.  
At the same time as P4 medicine is promoted as a participatory and 
“democratic” solution to the increasing costs of the medical system, it is also 
promised as a foundation for a “wellness industry” that will provide economic 
growth. Here, an expanded scope of medicine means expanded markets. 
Compared to the wide-ranging ambitions, proponents of P4 provide relatively 
few self-critical assessments and often promise a revolution in healthcare that is 
predicted not to happen now, but at a time-point that is conveniently beyond 
critical scrutiny, typically designated as “the near future” or “in 5, 10 or 20 
years time” (Flores et al., 2013; Hood et al., 2015; Topol, 2012, Vandamme 
2013). Lofty visions may be important to motivate scientific endeavors. 
However, pushing the envelope through rhetoric may also create unwarranted 
expectations and divert precious resources from other potentially productive 
activities. The shift of focus from culturally or structurally related causes of 
diseases (socio-economic factors, pollution, urban planning) to individualized 
preventive strategies must be backed up by evidence that this can improve 
health outcomes. Thus, the issue at stake is not only whether P4 strategies will 
give useful results, but also whether resources will be wasted that could be 
better spent elsewhere and whether less medicine in some contexts means 
more health. 
5. Conclusion 
We are currently witnessing visions of an unsurpassed expansion in 
medicalization with intensive monitoring of healthy people, creating huge 
datasets of enormous complexity. At the same time, we are witnessing an 
increasing realization that the social aspects of human life – or the human 
domain – is of crucial importance for discussions of the prospects of preventive 
medicine.  
To what extent, and how, P4 medicine will impact society and the socially 
embedded clinic remains an open question. Our intention has not been to 
dismiss its potential for improving biomedical research and public health. 
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Nevertheless, we have identified and analyzed tensions between the promise of 
in silico modelling of patient data and clinical in socio reality and discussed a 
number of concerns relating to personalized genomics and pilot projects for 
P4 medicine. The general problems facing preventive medicine in combination 
with the lack of evidence for the benefits and harms of P4 strategies make its 
proponents’ optimistic promises particularly suspicious. No in silico model to 
date, no professional, and certainly not people themselves are currently able to 
handle the data deluge. P4 medicine is thus currently starting to create a 
clinical situation that it cannot handle itself, but that it nonetheless promotes as 
a solution and introduces to the clinic and people´s lives. 
Moreover, the challenges of making people and society participate the way 
that the preventive strategies require are, although perhaps more banal than 
the scientific, maybe the most daunting. The lack of evidence that people react 
to risk information in the way that P4 proponents presuppose highlights a 
possible conflict between the professional ideal of P4 medicine and the social 
realm of human beings: Is risk information as “actionable” as assumed? Is 
health just one among many priorities for individuals? Just how far are we 
willing to go to achieve the goals of an optimal health? In this question, the 
conflict between the public´s idea of the "good life" and science´s definition 
of health will come to an ultimate test in P4 medicine. 
In summary, based on the historical and current challenges of preventive 
medicine, we find that the burden of proof for the benefits of P4 medicine 
should weigh heavily on those who make the promises. So far, such evidence is 
very limited compared to the indications that P4 medicine will increase the 
problems with traditional preventive medicine. Having examined early results 
from the HPWP, we may still conclude as Khoury et al. (2012, p. 642) that the 
“lack of information on the clinical utility for most proposed P4 applications 
produces an evidence dilemma and a conundrum for implementation into 
practice”. The high risk of unintentional harm and wasted resources raises an 
important question about the price we are willing to pay to explore the path of 
P4 medicine. In our view, until stronger evidence exists for health benefits and 
wider social implications, there are reasons to be highly skeptical of the 
promises of P4 medicine to offer society an economic boon and enable 
individuals to prevent future diseases. 
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